<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) is a complication of conventional <z:chebi fb="0" ids="35610">antineoplastic</z:chebi> therapy but has rarely been reported after autologous bone marrow transplantation (ABMT) </plain></SENT>
<SENT sid="1" pm="."><plain>We reviewed records of 206 patients who underwent ABMT for <z:hpo ids='HP_0002665'>lymphoma</z:hpo> at the University of Minnesota (Minneapolis, MN) between 1974 and 1993 </plain></SENT>
<SENT sid="2" pm="."><plain>Of 206 patients who underwent ABMT for non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) or <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>), 9 patients developed an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or secondary <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> between 5 and 60 months (median 34 months) post-BMT </plain></SENT>
<SENT sid="3" pm="."><plain>Two patients had relapsed after transplant and received additional therapy before the diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>They were censored from the statistical analysis, resulting in a cumulative incidence of 14.5% +/- 11.6% (95% confidence interval) at 5 years </plain></SENT>
<SENT sid="5" pm="."><plain>Three patients (15.2% +/- 18.0%) had <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>, and four (14.0% +/- 14.7%) had NHL </plain></SENT>
<SENT sid="6" pm="."><plain>In vitro BM purging had no affect on the incidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, although patients receiving peripheral blood stem cells had a projected <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> incidence of 31% +/- 33% versus 10.5% +/- 12% if BM cells were used (p = .0035) </plain></SENT>
<SENT sid="7" pm="."><plain>The patients had received a median of 14 cycles (range, 6 to 40) of chemotherapy before autologous transplantation; Five of nine patients received radiation therapy before BMT conditioning, and <z:hpo ids='HP_0000001'>all</z:hpo> patients received radiation before the diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>No BM cytogenetic abnormalities were evident pretransplant in three of three patients studied, and <z:hpo ids='HP_0000001'>all</z:hpo> nine had <z:mpath ids='MPATH_458'>normal</z:mpath> pretransplant BM <z:mp ids='MP_0000002'>morphology</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients had morphologic BM findings typical of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, and six of six studied had clonal cytogenetic abnormalities </plain></SENT>
<SENT sid="10" pm="."><plain>At the diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:hpo ids='HP_0000001'>all</z:hpo> nine patients were without clinical, radiographic, or autopsy evidence of recurrent <z:hpo ids='HP_0002665'>lymphoma</z:hpo>; Three of the nine patients have died from complications of cytopenias at 23, 36, and 45 months after transplant (3 to 10 months after the diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), whereas 6 survive 8 to 63 months after transplantation (1 to 34 months post-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="11" pm="."><plain>These data emphasize the cumulative leukemogenic potential of standard and salvage radiation and chemotherapy regimens and highlight treatment-induced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> as an important and frequent late complication of potentially curative BM transplant therapy </plain></SENT>
</text></document>